- Entheon Biomedical (ENBI) has announced updates to several of its strategic initiatives, including the previously announced launch of HaluGen’s Psychedelic Genetic Test kit
- The company continues to strengthen its strategic partnerships Divergence Neuro Tech and Heading Health for DMT research and ketamine-assisted therapy
- Part of its DMT research includes a clinical trial in The Netherlands and pre-clinical work at an Israeli CRO
- Entheon Biomedical is committed to developing safe and effective psychedelic medicines to provide patients with access to evidence-based treatments for addiction disorders.
- Entheon Biomedical Corp. (ENBI) is down 1.37 per cent and is trading at $0.36 per share
Entheon Biomedical (ENBI) has provided updates to several strategic initiatives, including the launch of HaluGen’s Psychedelic Genetic Test kit.
HaluGen Life Sciences, Entheon’s wholly-owned subsidiary, launched its psychedelics pre-screening platform and DNA test kit in Canada on April 6, 2021 and expects the kits to be available for sale in the US market by the end of May.
The first-of-its-kind psychedelics test kit provides genetic, personal, and familial insights to better inform one’s psychedelic assisted therapy experience.
“Not only does this kit represent a huge step forward for personalized medicine as it relates to psychedelic therapy, it is also Entheon’s first revenue stream. We anticipate strong market demand for this product; we’re currently working to develop commercial partnerships for the mass uptake of this test that will drive sales and revenue,” said Timothy Ko, Chief Executive Officer of Entheon.
Entheon continues to strengthen its strategic partnerships with other companies by progressing work with Divergence Neuro Tech on DMT research and with its more recent investment in Heading Health for ketamine-assisted therapy.
Part of its DMT research includes a clinical trial being conducted by the Centre for Human Drug Research in The Netherlands and new, pre-clinical work scheduled to begin late in the second quarter of 2021 at an Israeli clinical research organization.
“With those milestones and other necessary preparation, we continue to coordinate and prepare for the start of the Phase I clinical trial for DMT,” continued Timothy Ko.
The company recently completed a $3.17 million non-brokered private placement, raising its equity to $4.3 million and positioning it for increased revenue streams.
Entheon Biomedical is a research and development company committed to developing safe and effective psychedelic medicines to provide patients with access to evidence-based treatments for addiction disorders.
Entheon Biomedical Corp. (ENBI) is down 1.37 per cent and is trading at $0.36 per share as of 10:10 am ET.